Efficacy and Safety Evaluation of Absorbable and Moldable Skull Base Support Plates in Extended Endoscopic Endonasal Transsphenoidal Surgery: A Prospective, Randomized, Controlled Study

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age1-80
SponsorNanfang Hospital, Southern Medical University

About this trial

Primary objective: To evaluate the effect of absorbable and moldable skull base support plates used in extended endoscopic endonasal transsphenoidal surgery on the incidence of cerebrospinal fluid (CSF) rhinorrhea within 1 month after surgery.

Secondary objectives:

1. To evaluate the effect of absorbable and moldable skull base support plates used in extended endoscopic endonasal transsphenoidal surgery on the incidence of intracranial infection within 1 months after surgery; 2. To evaluate the effect of absorbable and moldable skull base support plates used in extended endoscopic endonasal transsphenoidal surgery on the duration of the surgery and length of postoperative hospital stay; 3. To monitor and evaluate the safety of absorbable and moldable skull base support plates, especially the occurrence of nasal complications.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged 1-80 years, regardless of gender;

Diagnosed with sellar region tumors confirmed by clinical symptoms, endocrine examinations, and imaging data;

Planned to undergo extended endoscopic endonasal transsphenoidal approach surgery as determined by departmental discussion;

Karnofsky Performance Status score ≥ 70, with an expected survival period ≥ 24 months;

Disqualifiers

Patients with other concurrent intracranial tumors or severe brain lesions;

Patients scheduled to undergo craniotomy or non-extended endoscopic endonasal transsphenoidal surgery;

Patients with uncontrolled severe heart, lung, kidney, or liver diseases;

Pregnant or lactating women;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Absorbable and moldable skull base support plate

    Device

    The sbsorbable and moldable skull base support plate is used during the skull base repair phase of the surgery. Trimming: Measure the size of the skull base defect bone window (from the tuberculum sellae to the clival bone edge). Cut the malleable support plate slightly longer than this dimension. Shaping: Shape the plate according to the morphological changes of the sellar floor bone resulting from the lesion. In cases with no obvious sellar floor bone destruction (e.g., suprasellar craniopharyngioma), the support plate is shaped into a slight "S" curve to ensure tight apposition to the dural window and the inlay artificial dura, preventing the formation of intervening gaps. Placement: Since the support plate requires tight embedding under the anterior and posterior bone edges, bone edges at the tuberculum sellae and clivus should be preserved during sellar floor drilling according to surgical exposure and plate embedding requirements to facilitate secure fixation.

Treatment groups

126 Participants
are divided into 2 treatment groups
Group A: Standard skull base reconstruction plus the absorbable and moldable skull base support plateExperimental treatment 1 intervention
Group B: Standard skull base reconstruction protocolNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Incidence of cerebrospinal fluid (CSF) rhinorrhea

Confirmed by combining clinical symptoms, imaging examinations, and nasal endoscopy, including but not limited to the following indicators: Clinical symptoms: persistent high fever (maximum temperature \> 38.5 °C for more than 3 days), nausea and vomiting, decreased consciousness, positive meningeal irritation signs, etc.; Imaging examinations: CT or MRI showing fluid accumulation in the paranasal sinuses, intracranial pneumocephalus, etc.; Nasal endoscopy demonstrating persistent cerebrospinal fluid leakage from the sellar floor wound.

Time frame
Within 1 month postoperatively

Secondary outcomes

1

Incidence of intracranial infection

Clinical symptoms: persistent high fever (maximum temperature \> 38.5 °C for more than 3 days), nausea and vomiting, decreased consciousness, positive meningeal irritation signs, etc.; Confirmed by pathogenic examination of cerebrospinal fluid via lumbar puncture.

Time frame
Within 1 month postoperatively

Other outcomes

1

Utilization rate of autologous fascia, fat, and pedicled mucosal flap

Utilization rate of autologous fascia, fat, and pedicled mucosal flap during the surgery.

Time frame
Intraoperative
2

Operation duration

Operation duration of the surgery

Time frame
Intraoperative
3

Length of postoperative hospital stay

Time spended in the hosptial after the surgery

Time frame
Within 1 month postoperatively
4

Incidence of long-term nasal complications

Evaluated based on the participant's symptom descriptions and otolaryngology outpatient assessments.

Time frame
Within 1 year postoperatively

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nanfang Hospital, Southern Medical University

Lead sponsor

First People's Hospital of Zhaoqing

Collaborator

Sun Yat-Sen University Cancer Center

Collaborator

Guangdong Provincial Hospital of Traditional Chinese Medicine

Collaborator

The People's Hospital of Gaozhou

Collaborator

First People's Hospital of Foshan

Collaborator

Huizhou Municipal Central Hospital

Collaborator

LiuZhou People's Hospital

Collaborator